2015 Kern Lipid Conference

 描述（由申请人提供）：克恩脂质会议于1985年首次召开，并继续每年举行一次，探讨脂质代谢与慢性人类疾病（如心脏代谢疾病、血脂异常、动脉粥样硬化、II型糖尿病和阿尔茨海默病）之间的复杂相互作用。克恩脂质会议的总体目标是：1）促进与脂质和脂蛋白代谢广泛领域相关的科学; 2）增加对血脂异常病理生物学的理解; 3）为来自学术界和工业界的科学家提供一个开放的论坛，以满足和讨论与脂质代谢相关的最新研究成果; 4）确保至少25%的与会者是早期职业科学家（研究生、博士后、助理教授）;以及5）提供独特的会议形式，其中50%的时间用于正式陈述，50%用于公开讨论陈述。2015年克恩脂质会议，题为“新兴疗法心血管疾病：学术和药物研究之间的对话”将于2015年8月3日至5日在韦尔万豪山庄在韦尔，CO.会议将共同主持罗伯特埃克尔，医学博士，伊拉戈德堡，医学博士，玛格丽特施瓦茨，博士和罗杰牛顿，博士。最近的临床研究强调了接受他汀类药物降低胆固醇的患者中后续心血管疾病（CVD）的剩余风险的重要性。这些数据沿着最近的遗传学研究，导致人们对进一步降低LDL的策略产生了极大的兴趣，并关注其他CVD风险因素，包括血液甘油三酯、Lp（a）水平升高和脂质诱导的组织炎症。这个高度互动的会议将促进学术和工业科学家之间的讨论。克恩会议将独特地关注脂质紊乱新疗法背后的生物学及其当前的药物开发。演讲者是国际公认的专家，采用各种实验方法，从基本机制的分子研究到动物生理学和人类临床干预研究。该计划将强调对演讲的深入讨论，这将为激发新的见解和开展新的合作提供机会，以进一步研究与血脂异常和CVD风险相关的生理学和病理生理学。此外，它应该激发新的想法，以进一步开发新的治疗方法。此外，重要的是，会议继续提供一个科学平台，鼓励早期职业科学家的参与，使他们能够与更成熟的研究人员深入讨论研究。

 DESCRIPTION (provided by applicant): The Kern Lipid Conference, which was first convened in 1985 and continues to be held annually, explores the complex interplay between lipid metabolism and chronic human disorders such as cardiometabolic diseases, dyslipidemia, atherosclerosis, type II diabetes and Alzheimer's disease. The overall goals of the Kern Lipid Conference are to: 1) promote science relating to broad areas of lipid and lipoprotein metabolism; 2) increase understanding of the pathobiology of dyslipidemia; 3) provide an open forum for scientists from both academia and industry to meet and discuss the latest research findings related to lipid metabolism; 4) ensure at least 25% of meeting participants are early career scientists (graduate students, postdoctoral fellows, and Assistant Professors); and 5) to provide a unique meeting format in which 50% of the time is devoted to formal presentations and 50% is for open discussions of the presentations. The 2015 Kern Lipid Conference, entitled "Emerging therapies for cardiovascular diseases: A dialogue between academic and pharmaceutical research" will be held August 3-5, 2015 at the Vail Marriott Mountain Resort in Vail, CO. The Conference will be co-chaired by Robert Eckel, MD, Ira Goldberg, MD, Margrit Schwarz, PhD, and Roger Newton, PhD. Recent clinical studies have highlighted the importance of residual risk for subsequent cardiovascular disease (CVD) in patients receiving statin medications for cholesterol reduction. These data along with recent genetic studies have led to extraordinary interest in further LDL reduction strategies as well as a focus on other CVD risk factors, including elevated levels of blood triglycerides, Lp(a), and lipid-induced tissue inflammation. This highly interactive meeting will foster discussion between academic and industrial scientists. The Kern Conference ill uniquely focus on the biology behind novel therapies for lipid disorders and their current pharmaceutical development. The speakers are internationally recognized experts and employ a variety of experimental approaches ranging from molecular investigations of basic mechanisms to studies of animal physiology and human clinical interventions. The program will emphasize in-depth discussions of the presentations, which will provide an opportunity to stimulate new insights and initiate new collaborations to further the investigation of the physiology and pathophysiology associated with dyslipidemia and CVD risk. In addition, it should stimulate new ideas to further the development of novel therapies. Also, and importantly, the meeting continues to provide a scientific platform that encourages the participation of early career scientists, enabling them to discuss research in depth with more established investigators.